A phase III randomised trial of cisplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group.

Superior localisation and imaging of radiolabelled monoclonal antibody E48 F(ab'), fragment in xenografts of human squamous cell carcinoma of the head and neck and of the vulva as compared to monoclonal antibody E48 IgG Summary Monoclonal antibody (MAb) E48 and its F(ab')2 fragment, radiolabelled with "'I, were tested for tumour localisation and imaging in nude mice bearing a squamous cell carcinoma xenograft line derived from a head and neck carcinoma (HNX-HN) or from a vulva carcinoma (VX-A431). MAb IgG or F(ab')2 fragments were injected in parallel and at day 1, 2, 3 and 6 or 7, mice were either scanned with a gamma camera or dissected for determination of isotope biodistribution. In HNX-HN bearing mice, E48 IgG as well as F(ab')2 showed highly specific localisation in tumour tissue. The mean tumour uptake (n = 4) expressed as the percentage of the injected dose per gram of tumour tissue (percentage ID/g) of IgG was 11.9% at day 1 and increased to 14.6% at day 6 whereas percentage ID/g of F(ab')2 was 7.2% at day 1 and decreased during subsequent days. Tumour to blood ratios (T/B) at day I were 1.2 for IgG and 13.6 for F(ab')2 and reached a maximum at day 6 with values of 6.4 and 54.2 respectively. In VX-A431 bearing mice, only E48 F(ab')2 showed preferential localisation in tumour tissue. At day 1, Percentage ID/g of IgG was 3.7 and T/B was 0.3, while percentage ID/g of F(ab')2 was 2.4 and T/B was 3.2. Percentage ID/g decreased after day I while T/B increased. In these experiments no preferential localisation of either isotype matched '251I-labelled control IgG or F(ab')2 was observed. In F(ab')2 injected HNX-HN bearing mice as well as VX-A431 bearing mice, tumours could be visualised at day 1 and 2 without any appreciable background activity. With MAb IgG this was also possible in HNX-HN bearing mice (but not in VX-A431 bearing mice) but only at day 3 and 6. These findings suggest that the superior tumour to non-tumour ratios render the E48 F(ab')2 fragment more qualified for specific targeting of radioisotopes to tumour xenografts in this experimental setting. Of all human neoplasms, squamous cell carcinoma (SCC) is one of the most common tumour types and represents the major histological type of neoplasm arising from head and neck, cervix, skin, and lung. The relative sensitivity of head and neck SCC for radiation therapy has led us to investigate …

[1]  D. Hedley Flow cytometry using paraffin-embedded tissue: five years on. , 1989, Cytometry.

[2]  J. Brierley Classification of Malignant Tumours , 1963, British medical journal.

[3]  L L Vindeløv,et al.  A review of techniques and results obtained in one laboratory by an integrated system of methods designed for routine clinical flow cytometric DNA analysis. , 1990, Cytometry.

[4]  W. McGuire,et al.  Ploidy, proliferative activity and prognosis. DNA flow cytometry of solid tumors , 1990, Cancer.

[5]  D. Haines,et al.  A novel marker for basal (stem) cells of mammalian stratified squamous epithelia and squamous cell carcinomas. , 1989, Cancer research.

[6]  F. Muggia,et al.  Role of chemotherapy in head and neck cancer: systemic use of single agents and combinations in advanced disease. , 1980, Head & Neck Surgery.

[7]  D. Spandidos,et al.  Clinical relevance of oncogene expression in head and neck tumours. , 1986, Anticancer research.

[8]  P. Bunn,et al.  Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. , 1984, Journal of immunological methods.

[9]  O. Mjølnerød,et al.  DNA‐ploidy as prognostic factor in prostatic carcinoma , 1990, International journal of cancer.

[10]  W. Fee,et al.  Reactivity of monoclonal antibody 17.13. with human squamous cell carcinoma and its application to tumor diagnosis. , 1987, Cancer research.

[11]  A. Wein,et al.  Simultaneous flow cytometric deoxyribonucleic acid and acid phosphatase analysis of benign and malignant lesions of the prostate. , 1985, The Journal of urology.

[12]  L. Layfield,et al.  Relationship of DNA content to conventional prognostic factors in clinically localised carcinoma of the prostate. , 1988, British journal of urology.

[13]  I. Christensen,et al.  A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. , 1983, Cytometry.

[14]  M. Herlyn,et al.  Development of monoclonal antibodies that recognize antigens associated with human cervical carcinoma. , 1986, Acta cytologica.

[15]  J. Bulte,et al.  Monoclonal antibody JSB‐1 detects a highly conserved epitope on the P‐glycoprotein associated with multi‐drug‐resistance , 1988, International journal of cancer.

[16]  M. Namba,et al.  Monoclonal antibodies against human oral squamous cell carcinoma reacting with keratin proteins , 1987, Cancer.

[17]  F. Askin,et al.  Significance of ploidy in laryngeal cancer. , 1986, American journal of surgery.

[18]  J. Jacobs,et al.  A randomized trial of cisplatin (CACP) + 5‐fluorouracil (5‐FU) infusion and CACP + 5‐FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck , 1985, Cancer.

[19]  G. Murphy,et al.  LNCaP model of human prostatic carcinoma. , 1983, Cancer research.

[20]  T. Therneau,et al.  Stage C prostatic adenocarcinoma: flow cytometric nuclear DNA ploidy analysis. , 1989, Mayo Clinic proceedings.

[21]  E. Haber,et al.  Immunogenicity and kinetics of distribution and elimination of sheep digoxin-specific IgG and Fab fragments in the rabbit and baboon. , 1979, Clinical and experimental immunology.

[22]  J. Wilson,et al.  Factors predicting response of end stage squamous cell carcinoma of the head and neck to cisplatinum. , 1987, Clinical otolaryngology and allied sciences.

[23]  B. Brenner,et al.  Monoclonal antibodies to human lung tumor antigens demonstrated by immunofluorescence and immunoprecipitation. , 1982, Cancer research.

[24]  R. Vessella,et al.  Correlation of vascular permeability and blood flow with monoclonal antibody uptake by human Clouser and renal cell xenografts. , 1988, Cancer research.

[25]  N. Jambhekar,et al.  Monoclonal antibody against human squamous‐cell‐carcinoma‐associated antigen , 1989, International journal of cancer.

[26]  F. Habib,et al.  Nuclear DNA analysis of prostate tissues: correlation with stage and grade of tumour. , 1989, Urologia internationalis.

[27]  W. Dixon,et al.  BMDP statistical software , 1983 .

[28]  M. Gerretsen,et al.  Detection of squamous cell carcinoma xenografts in nude mice by radiolabeled monoclonal antibody E48. , 1991, Archives of otolaryngology--head & neck surgery.

[29]  I. Bernstein,et al.  In vitro measurement of avidity of radioiodinated antibodies. , 1987, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[30]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[31]  R. Wahl,et al.  Improved radioimaging and tumor localization with monoclonal F(ab')2. , 1983, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[32]  T. Therneau,et al.  Stage D1 prostatic adenocarcinoma: significance of nuclear DNA ploidy patterns studied by flow cytometry. , 1988, Mayo Clinic proceedings.

[33]  O. Kallioniemi Comparison of fresh and paraffin-embedded tissue as starting material for DNA flow cytometry and evaluation of intratumor heterogeneity. , 1988, Cytometry.

[34]  T. Koyanagi,et al.  Establishment of Monoclonal Antibody to Human Androgen Receptor and Its Clinical Application for Prostatic Cancers , 1988, American journal of clinical oncology.

[35]  S. Jones,et al.  Monoclonal antibodies to human squamous cell carcinoma of the lung and their application to tumor diagnosis. , 1985, Cancer research.

[36]  J. Adolfsson,et al.  The prognostic value of modal deoxyribonucleic acid in low grade, low stage untreated prostate cancer. , 1990, The Journal of urology.

[37]  P. Bradley,et al.  Induction VBM plus radiotherapy, versus radiotherapy alone for advanced head and neck cancer: long-term results. , 1989, Clinical otolaryngology and allied sciences.

[38]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[39]  D. Schwartz,et al.  Antibodies to human squamous cell carcinoma , 1983, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[40]  J. Jett,et al.  MATHEMATICAL ANALYSIS OF DNA DISTRIBUTIONS DERIVED FROM FLOW MICROFLUOROMETRY , 1974, The Journal of cell biology.

[41]  R. E. Cunningham,et al.  Prognostic significance of DNA ploidy in carcinoma of prostate. , 1989, Urology.

[42]  J. Isaacs,et al.  Biology and therapy of prostatic cancer. , 1986, Cancer surveys.

[43]  W. Greco,et al.  Proliferative characteristics of primary and metastatic human solid tumors by DNA flow cytometry. , 1984, Cytometry.

[44]  V. Zurawski,et al.  Iodination of monoclonal antibodies for diagnosis and radiotherapy using a convenient one vial method. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[45]  G. Snow,et al.  A 22-kd surface antigen detected by monoclonal antibody E 48 is exclusively expressed in stratified squamous and transitional epithelia. , 1990, The American journal of pathology.

[46]  T. Carey,et al.  Altered expression in squamous carcinoma cells of an orientation restricted epithelial antigen detected by monoclonal antibody A9. , 1986, Cancer research.

[47]  P. Humphrey,et al.  Comparative localization of murine monoclonal antibody Me1-14 F(ab')2 fragment and whole IgG2a in human glioma xenografts. , 1988, Cancer research.

[48]  P. Okunieff,et al.  Blood flow, metabolism, cellular microenvironment, and growth rate of human tumor xenografts. , 1989, Cancer research.

[49]  D. Paulson,et al.  Flow cytometric determination of ploidy in prostatic adenocarcinoma: a comparison with seminal vesicle involvement and histopathological grading as a predictor of clinical recurrence. , 1988, The Journal of urology.

[50]  R. Gelber,et al.  Association of DNA index and S-phase fraction with prognosis of nodes positive early breast cancer. , 1987, Cancer research.

[51]  M. Melamed,et al.  Flow cytometry of prostate cancer: relationship of DNA content to survival. , 1987, Cancer research.

[52]  I W Taylor,et al.  Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. , 1983, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[53]  J. Dodd,et al.  Epidermal growth factor receptor mRNA levels in human prostatic tumors and cell lines. , 1990, The Journal of urology.

[54]  G. Snow,et al.  Localization and imaging of radiolabelled monoclonal antibody against squamous‐cell carcinoma of the head and neck in tumor‐bearing nude mice , 1989, International journal of cancer.

[55]  T. Visakorpi,et al.  Improved prognostic impact of S-phase values from paraffin-embedded breast and prostate carcinomas after correcting for nuclear slicing. , 1991, Cytometry.

[56]  J. Bertino,et al.  The role of chemotherapy in the management of cancer of the head and neck: A review , 1975, Cancer.

[57]  R. Reisfeld,et al.  Antigens associated with human squamous cell lung carcinoma defined by murine monoclonal antibodies. , 1986, Cancer research.

[58]  Robert W. McDivitt,et al.  A proposed classification of breast cancer based on kinetic information derived from a comparison of risk factors in 168 primary operable breast cancers , 1986, Cancer.

[59]  G. Williams,et al.  Prostatic carcinoma cell DNA content measured by flow cytometry and its relation to clinical outcome , 1986, The British journal of surgery.

[60]  D. Karnofsky The clinical evaluation of chemotherapeutic agents in cancer , 1949 .

[61]  D.,et al.  Regression Models and Life-Tables , 2022 .

[62]  J. Jacobs,et al.  Squamous Cell Carcinoma of the Head and Neck , 2006 .

[63]  E. Thonar,et al.  Biochemical studies of the matrix of craniovertebral chordoma and a metastasis , 1979, Cancer.

[64]  S. Vogl,et al.  Chemotherapy of advanced head and neck cancer with methotrexate, bleomycin, and cis‐diamminedichloroplatinum II in an effective outpatient schedule , 1979, Cancer.

[65]  W. Mooi,et al.  Localization of monoclonal antibody auai and its F(ab')2 fragments in human tumour xenografts: An autoradiographic and immunohistochemical study , 1988, International journal of cancer. Supplement = Journal international du cancer. Supplement.